Connect with us


Roche Will Pay Up to €2.8 Billion for Carmot Therapeutics

Roche is set to acquire Carmot Therapeutics, along with three clinical-stage assets for treating obesity and diabetes, for a maximum of €2.85 billion. The agreement involves a cash payment of $2.7 billion (€2.48 billion) at the transaction’s closure, with additional payments of up to $400 million (€367 million) contingent on specified milestones.




Roche, the Basel-based laboratory has reached an agreement to buy Carmot Therapeutics, including three clinical-stage assets for the treatment of obesity and diabetes, for a maximum amount of €2.85 billion

Under the terms of the agreement, Roche will pay $2.7 billion (€2.48 billion) in cash upon closing of the transaction. In this operation, Carmot shareholders will be entitled to receive payments of up to $400 million (€367 million) depending on the achievement of certain milestones.

Closing of the transaction is currently expected to occur during the first quarter of 2024. Upon closing of the transaction, Roche will gain access to Carmot’s existing R&D portfolio, including all clinical and preclinical assets, in addition to incorporating its employees as part of the pharmaceutical division.

Roshe CEO Thomas Schinecker maintains that “obesity is a heterogeneous disease, contributing to many other diseases, which together constitute a significant health burden worldwide.”

If you want to find more about Roche and the acquisition of Carmot Therapeutics, and to find the most important business news of the day, download for free our companion app Born2Invest.

“By combining the Carmot portfolio with programs from our portfolio of pharmaceutical products and our expertise in diagnostics, we aim to improve the level of care and positively impact the lives of patients,” concludes the manager.

A little over a month ago, the Swiss laboratory already acquired Telavant Holdings, a company owned 75% by Roivant Sciences and 25% by Pfizer, for €6.7 billion. All of this in an agreement in which the Swiss multinational will pay a purchase price of €6.7 billion in advance and a short-term milestone payment of €141 million.

Following the closing of the transaction, Roche will obtain the rights to develop, manufacture and market the drug RVT-3101 in the United States and Japan , while in the rest of the world the marketing rights will correspond to Pfizer.

Roche is a multinational pharmaceutical company of Swiss origin, headquartered in Basel, specialized in the research and development of medicines and diagnostic products. The company was established in 1896 by its founder Fritz Hoffmann-La Roche. The pharmaceutical group is operationally present in more than one hundred countries.


(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.